This website uses cookies for a range of purposes to help us understand your interests and improve the website. By using our website, you acknowledge the use of essential cookies and consent to the use of non-essential cookies, as described in our Cookie Policy. To understand more about how we use cookies or to change your preference and browser settings, please see our Cookie policy

Back toDeals, Cases & Projects
Advanced
Filters

Milestone Pharmaceuticals Announces Pricing of C$30M Public Offering

Date Closed

March 4, 2024

Lead Office

Québec City

Value

30.00 Million CAD

On February 29, 2024, Milestone Pharmaceuticals ("Milestone") announced the pricing of its C$30 Million public offering of common shares and pre-funded warrants. A total of 16,666,667 common shares at a public offering price of $1.50 per share and pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant were offered. Milestone is expecting to use the proceeds to continue the development of etripamil in its lead indication of paroxysmal supraventricular tachycardia (PSVT) and its subsequent indication of atrial fibrillation with rapid ventricular rate (AFib-RVR).

Milestone, headquartered in Montréal, Québec, is a drug development company that focuses on cardiovascular health.

McCarthy Tétrault advised the underwriters with Piper Sandler & Co. acting as bookrunning manager and H.C. Wainwright & Co. as lead manager with a team comprised of Andrew Parker, Charles-Antoine Soulière and Vincent Laurin (Capital Markets) and Marie-Soleil Landry and Geneviève Favreau (Tax).

People